Close
Back to 4151 Stock Lookup

(4151) – StreetInsider.com Reports

Sep 25, 2023 06:56 AM Ardelyx (ARDX) Announces Tenapanor for Hyperphosphatemia Approved in Japan
Dec 5, 2022 05:03 PM MEI Pharma (MEIP) and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
Nov 18, 2022 08:01 AM Kyowa Kirin and MEI Pharma (MEIP) Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan
May 17, 2022 08:03 AM Mereo BioPharma (MREO) Announces Appointment of Dr. Abdul Mullick to Board of Directors
May 9, 2022 09:15 AM Cumberland Pharmaceuticals (CPIX) Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso
Mar 24, 2022 04:02 PM MEI Pharma (MEIP) says FDA informed the companies of its position that a randomized trial is now needed to adequately assess drug efficacy and safety of PI3K inhibitor drug candidates
Jan 4, 2022 09:15 AM Cumberland Pharmaceuticals (CPIX) Acquires Sancuso From Kyowa Kirin North America
Nov 10, 2021 08:15 AM MEI Pharma (MEIP) and Kyowa Kirin receive Orphan Drug Designation for Zandelisib for the Treatment of Follicular Lymphoma
May 19, 2021 05:03 PM MEI Pharma (MEIP) and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021
May 12, 2021 10:02 AM MEI Pharma (MEIP), Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress
Oct 12, 2020 08:07 AM Ardelyx (ARDX) Announces Data Supporting Efficacy and Safety of Tenapanor to be Presented at ASN
Apr 14, 2020 07:06 AM MEI Pharma (MEIP), Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401
Feb 27, 2020 08:06 AM Ultragenyx Pharma (RARE), Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita for TIO
Sep 10, 2019 09:04 AM Ultragenyx Pharma (RARE), Kyowa Kirin Announce Intent to Submit sBLA to U.S. FDA for Crysvita in TIO
Aug 1, 2019 06:36 AM Kyowa Kirin Buys Back Tivozanib Non-Oncology Rights from AVEO Oncology (AVEO)
Nov 5, 2018 08:04 AM MEI Pharma (MEIP), Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan
Feb 23, 2018 08:07 AM Kyowa Kirin, Ultragenyx (RARE) Announce Crysvita Receives Conditional Marketing Authorisation in Europe for Treatment of X-Linked Hypophosphatemia in Children

Back to 4151 Stock Lookup